Vaccine Adjuvants Market Size And Forecast By Type (Pathogen, Adjuvant Emulsion, Particulate), By Route of Administration (Oral, Intradermal, Intranasal, Intramuscular), By Application, And Trend Analysis, 2014 - 2025

Published: Sep, 2017 | Pages: 90 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global vaccine adjuvants market is expected to reach USD 758.8 million by 2025, according to a new report by Grand View Research, Inc. The significance of adjuvant research in the development of vaccines has increased gradually due to inadequate immunogenicity of innovative vaccine antigens. In addition, the growing focus on long-lasting immunization effect against existing and emerging diseases is expected to boost the demand for vaccine adjuvants.

Furthermore, rising prevalence of cervical cancer is anticipated to boost the market. According to NCBI, around 15,000 females die every year due to cervical cancer. There are certain companies developing vaccine adjuvants for this type of cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human papillomavirus vaccine) by GSK, which boosts the immune response for a longer duration.

Further key findings from the report suggest:

• Particulate product type dominated the market in 2016 due to greater efficiency of vaccines, presence of wide range of products, easier availability, and improved safety

• Pathogen is anticipated to be the fastest growing segment with a CAGR of 11.9% due to the availability of naturally occurring pathogens used as adjuvants

• Among the route of administration, intramuscular held the largest market share in 2016 due to the high immune specificity of vaccines

• Infectious disease segment dominated the market in 2016 by application, due to the increasing prevalence of infectious diseases such as hepatitis A, B, C, influenza, meningitis, and others

• Cancer is expected to be the fastest growing application segment because of the rising prevalence of cancer and growing R&D activities to treat various types of cancer

• Geographically, North America held the largest market share due to increase in favorable government initiatives and presence of well-established healthcare services.

• Asia Pacific is estimated to be the fastest growing region over the forecast period with a significant CAGR from 2017 to 2025 due to the presence of huge target population and rise in disposable income

• Some of the key players of the market include GlaxoSmithKline plc.; Novavax, Inc.; Adjuvance Technologies, Inc.; SPI Pharma; Agenus, Inc.; CSL Limited; InvivoGen; and Brenntag Biosector

• Most of the key participants are focusing on strategies such as mergers & acquisitions, collaborations, and expansion of their product portfolios

• In December 2015, SPI Pharma agreed to collaborate with Asahi Kasei Corporation. Both the companies agreed to sell each other's products in their respective markets: Japan and North America.

 Table of Contents

Chapter 1 Methodology and Scope
                 1.1 Information Procurement
                     1.1.1 Purchased database:
                     1.1.2 GVR's internal database
                 1.2 Research Methodology
                 1.3 Geographic Scope & Assumptions
                 1.4 Region-wise Market Calculation
                     1.4.1 Region-wise market: Base estimates
                     1.4.2 Global market: CAGR calculation
                 1.5 Region-based Segment Share Calculation
                 1.6 List of Secondary Sources
Chapter 2 Executive Summary
                 2.1 Market Snapshot
Chapter 3 Vaccine Adjuvants Market Variables, Trends, & Scope
                 3.1 Market Segmentation & Scope
                 3.2 Market Size and Growth Prospects
                     3.2.1 Market driver analysis
                         3.2.1.1 Rise in importance of immunization across the globe
                         3.2.1.2 High predominance of chronic diseases
                         3.2.1.3 Technologic advancements in the types of vaccines
                         3.2.1.4 Other drivers
                     3.2.2 Market restraint analysis
                         3.2.2.1 Cost of immunization
                         3.2.2.2 Lack of healthcare infrastructure
                 3.3 Penetration & Growth Prospect Mapping
                 3.4 Vaccine Adjuvants - SWOT Analysis, by Factor (Political & legal, economic, and technological)
                 3.5 Industry Analysis - Porter's
Chapter 4 Vaccine Adjuvants Market: Type Estimates & Trend Analysis
                 4.1 Vaccine Adjuvants Market: Vaccine Type Movement Analysis
                 4.2 Pathogen
                     4.2.1 Pathogen market, 2014 - 2025 (USD Million)
                 4.3 Adjuvant Emulsion
                     4.3.1 Adjuvant emulsion market, 2014 - 2025 (USD Million)
                 4.4 Particulate
                     4.4.1 Particulate market, 2014 - 2025 (USD Million)
                 4.5 Combination
                     4.5.1 Combination market, 2014 - 2025 (USD Million)
                 4.6 Others
                     4.6.1 Others market, 2014 - 2025 (USD Million)
Chapter 5 Vaccine Adjuvants Market: Application Estimates & Trend Analysis
                 5.1 Vaccine Adjuvants Market: Application Movement Analysis
                 5.2 Infectious Diseases
                     5.2.1 Infectious diseases market, 2014 - 2025 (USD Million)
                 5.3 Cancer
                     5.3.1 Cancer market, 2014 - 2025 (USD Million)
                 5.4 Others
                     5.4.1 Others market, 2014 - 2025 (USD Million)
Chapter 6 Vaccine Adjuvants Market: Administration Estimates & Trend Analysis
                 6.1 Vaccine Adjuvants Market: Vaccine Administration Movement Analysis
                 6.2 Oral
                     6.2.1 Oral market, 2014 - 2025 (USD Million)
                 6.3 Intradermal
                     6.3.1 Intradermal market, 2014 - 2025 (USD Million)
                 6.4 Intranasal
                     6.4.1 Intranasal market, 2014 - 2025 (USD Million)
                 6.5 Intramuscular
                     6.5.1 Intramuscular market, 2014 - 2025 (USD Million)
                 6.6 Others
                     6.6.1 Others market, 2014 - 2025 (USD Million)
Chapter 7 Vaccine Adjuvants Market: Regional Estimates & Trend Analysis, By Administration, Type & Application
                 7.1 Vaccine Adjuvants Market: Vaccine Regional Movement Analysis
                 7.2 North America
                     7.2.1 North America vaccine adjuvants market, 2014 - 2025 (USD Million)
                     7.2.2 U.S.
                         7.2.2.1 U.S. vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
                         7.2.2.2 U.S. vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
                         7.2.2.3 U.S. vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
                     7.2.3 Canada
                         7.2.3.1 Canada vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
                         7.2.3.2 Canada vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
                         7.2.3.3 Canada vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
                 7.3 Europe
                     7.3.1 Europe vaccine adjuvants market, 2014 - 2025 (USD Million)
                     7.3.2 Germany
                         7.3.2.1 Germany vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
                         7.3.2.2 Germany vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
                         7.3.2.3 Germany vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
                     7.3.3 UK
                         7.3.3.1 UK vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
                         7.3.3.2 UK vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
                         7.3.3.3 UK vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
                 7.4 Asia Pacific
                     7.4.1 Asia Pacific vaccine adjuvants market, 2014 - 2025 (USD Million)
                     7.4.2 China
                         7.4.2.1 China vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
                         7.4.2.2 China vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
                         7.4.2.3 China vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
                     7.4.3 Japan
                         7.4.3.1 Japan vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
                         7.4.3.2 Japan vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
                         7.4.3.3 Japan vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
                 7.5 Latin America
                     7.5.1 Latin America vaccine adjuvants market, 2014 - 2025 (USD Million)
                     7.5.2 Brazil
                         7.5.2.1 Brazil vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
                         7.5.2.2 Brazil vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
                         7.5.2.3 Brazil vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
                 7.6 MEA
                     7.6.1 MEA vaccine market, 2014 - 2025 (USD Million)
                     7.6.2 South Africa
                         7.6.2.1 South Africa vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
                         7.6.2.2 South Africa vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
                         7.6.2.3 South Africa vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
Chapter 8 Competitive Landscape
                 8.1 Strategy Framework
                 8.2 Company Profiles
                     8.2.1. GSK
                         8.2.1.1. Company overview
                         8.2.1.2. Financial performance
                         8.2.1.3. Product benchmarking
                         8.2.1.4. Strategic initiatives
                     8.2.2. Novartis/CSL
                         8.2.2.1. Company overview
                         8.2.2.2. Product benchmarking
                         8.2.2.3. Strategic initiatives
                     8.2.3. Agenus
                         8.2.3.1. Company overview
                         8.2.3.2. Financial performance
                         8.2.3.3. Product benchmarking
                         8.2.3.4. Strategic initiatives
                     8.2.4. Adjuvance
                         8.2.4.1. Company overview
                         8.2.4.2. Financial performance
                         8.2.4.3. Product benchmarking
                         8.2.4.4 Strategic initiatives
                     8.2.5. Novavax
                         8.2.5.1. Company overview
                         8.2.5.2. Financial performance
                         8.2.5.3. Product benchmarking
                     8.2.6. SPI Pharma
                         8.2.6.1. Company overview
                         8.2.6.2. Financial performance
                         8.2.6.3. Product benchmarking
                     8.2.7. Invivogen
                         8.2.7.1. Company overview
                         8.2.7.2. Financial performance
                         8.2.7.3. Product benchmarking
                         8.2.7.4. Strategic initiatives
                     8.2.8. Avanti Polar Lipids
                         8.2.8.1. Company overview
                         8.2.8.2. Financial performance
                         8.2.8.3. Product benchmarking
                         8.2.8.4. Strategic initiatives
                     8.3.9. Brentagg
                         8.2.9.1. Company overview
                         8.2.9.2. Financial performance
                         8.2.9.3. Product benchmarking
                         8.2.9.4. Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 3 North America vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 4 North America vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 5 U.S. vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 6 U.S. vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 7 U.S. vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 8 Canada vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 9 Canada vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 10 Canada vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 11 Europe vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 12 Europe vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 13 Europe vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 14 Germany vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 15 Germany vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 16 Germany vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 17 UK vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 18 UK vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 19 UK vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 20 Asia Pacific vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 21 Asia Pacific vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 22 Asia Pacific vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 23 China vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 24 China vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 25 China vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 26 Japan vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 27 Japan vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 28 Japan vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 29 Latin America vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 30 Latin America vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 31 Latin America vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 32 Brazil vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 33 Brazil vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 34 Brazil vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 35 MEA vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 36 MEA vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 37 MEA vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)
TABLE 38 South Africa vaccine adjuvants market, by type, 2014 - 2025 (USD Million)
TABLE 39 South Africa vaccine adjuvants market, by application, 2014 - 2025 (USD Million)
TABLE 40 South Africa vaccine adjuvants market, by administration, 2014 - 2025 (USD Million)